Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for the treatment of endometrial cancer in settings with limited resources: report from the International Gynecological Cancer Society consensus meeting.

Frontiers in oncology·2026
Same author

Global consensus for the screening, diagnosis, staging, treatment, and surveillance of ovarian cancer in areas of significant resource limitations: report from the International Gynecological Cancer Society consensus meeting.

Frontiers in oncology·2026
Same author

The International Gynecologic Cancer Society Global Fellowship Program: advancing access to gynecologic oncology and surgical care worldwide.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Comparison of clinical and cost outcomes between primary and interval debulking surgery in ovarian cancer.

Singapore medical journal·2025
Same author

A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11).

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

The role of surgery in gestational trophoblastic disease: an overview.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Related Experiment Video

Updated: May 25, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Epithelial ovarian cancer.

Joseph S Ng1, Jeffrey J H Low, A Ilancheran

  • 1Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, NUHS Tower Block, Singapore, Singapore. drjoeng@nus.edu.sg

Best Practice & Research. Clinical Obstetrics & Gynaecology
|January 28, 2012
PubMed
Summary

Fertility-sparing surgery is a viable option for young women with early-stage epithelial ovarian cancer, preserving reproductive potential without compromising survival outcomes. Adjuvant chemotherapy is recommended and does not increase risks for future pregnancies.

More Related Videos

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Experiment Videos

Last Updated: May 25, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Area of Science:

  • Gynecologic Oncology
  • Reproductive Endocrinology
  • Surgical Oncology

Background:

  • Epithelial ovarian cancer (EOC) in women aged 40 or younger presents unique management challenges, necessitating a balance between effective cancer treatment and reproductive potential preservation.
  • The incidence of EOC in this demographic ranges from 3-17%.

Purpose of the Study:

  • To evaluate the efficacy and safety of fertility-sparing surgical approaches in young women diagnosed with early-stage epithelial ovarian cancer.
  • To assess the impact of adjuvant therapies on oncologic outcomes and subsequent pregnancy health.

Main Methods:

  • Review of management strategies for premenopausal women with EOC.
  • Analysis of outcomes associated with fertility-sparing surgery, including staging and cytoreductive procedures.
  • Evaluation of adjuvant chemotherapy, targeted therapy, and ovarian cryopreservation in this patient population.

Main Results:

  • Fertility-sparing surgery, involving complete staging and cytoreduction while retaining reproductive organs, demonstrates equivalent oncologic and clinical outcomes compared to standard treatments.
  • Adjuvant platinum-taxane chemotherapy, when indicated, improves cancer and survival outcomes.
  • Adjuvant treatment does not appear to elevate the risk of congenital anomalies in subsequent pregnancies.

Conclusions:

  • Fertility-sparing surgery is a recommended approach for select young women with early-stage EOC, effectively balancing cancer treatment with reproductive preservation.
  • Platinum-taxane adjuvant chemotherapy is advised for indicated cases, enhancing patient outcomes.
  • Ovarian cryopreservation and targeted therapies are considered experimental and not part of the current standard of care.